Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 193 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard COVID-19 therapies Clear all
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

NCT01808820
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions
Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
Biological · Drug · Procedure
Lead sponsor
Macarena De La Fuente, MD
Other
Eligibility
13 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients

NCT03276559
View directory record Official record
Conditions
Critical Illness, Communication Disabilities
Interventions
EMPOWER, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
3
States / cities
Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Results available

N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

NCT04706416
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
N-acetyl glucosamine (NAG), Control
Dietary Supplement · Other
Lead sponsor
Quantinosis.ai LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 2 Interventional

Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19

NCT04438057
View directory record Official record
Conditions
COVID-19
Interventions
CCP
Biological
Lead sponsor
Metro Infectious Disease Consultants
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Burr Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

NCT04363736
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Tociliuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
24
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

NCT04373044
View directory record Official record
Conditions
Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Baricitinib, Hydroxychloroquine, Placebo Administration
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT04305457
View directory record Official record
Conditions
Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Shreveport, Louisiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Early Phase 1 Interventional

Convalescent Plasma in Pediatric COVID-19

NCT04458363
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma (CP), Standard COVID-19 therapies
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
0 Years to 22 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Results available

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

NCT04411667
View directory record Official record
Conditions
Sars-CoV2
Interventions
Octagam
Drug
Lead sponsor
George Sakoulas, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab With DC Vaccines for Recurrent Brain Tumors

NCT02529072
View directory record Official record
Conditions
Malignant Glioma, Astrocytoma, Glioblastoma
Interventions
nivolumab, DC
Drug · Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 11, 2026, 8:55 AM EDT
Completed No phase listed Observational

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

NCT04884477
View directory record Official record
Conditions
COVID-19, Immunosuppressed Host, Convalescent Plasma, Anti-CD20 Therapy
Interventions
Convalescent Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

NCT04662060
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Phase 3 Interventional Results available

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990
View directory record Official record
Conditions
Infectious Pneumonia, Severe COVID-19
Interventions
Reparixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Not applicable Interventional Results available

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04382391
View directory record Official record
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897
View directory record Official record
Conditions
COVID-19
Interventions
Brilacidin, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Winfield, Illinois • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 11, 2026, 8:55 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

NCT04412252
View directory record Official record
Conditions
COVID-19
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Hartford, Connecticut • Iowa City, Iowa • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 11, 2026, 8:55 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 11, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

NCT04590586
View directory record Official record
Conditions
COVID-19
Interventions
Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 11, 2026, 8:55 AM EDT